Armata Pharmaceuticals (ARMP) Non-Current Assets (2013 - 2026)

Armata Pharmaceuticals has disclosed Non-Current Assets across 14 years of filings, most recently posting $63.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $63.9 million, down 13.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $275.9 million (down 8.78% YoY), and the FY2025 annual result was $66.2 million, down 11.87% from the prior year.
• Non-Current Assets came in at $63.9 million for Q1 2026 at Armata Pharmaceuticals, down from $66.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $79.2 million in Q4 2023 to a low of $59.1 million in Q1 2022.
• The 5-year median for Non-Current Assets is $73.3 million (2025), against an average of $70.8 million.
• Across the five-year window, Non-Current Assets surged 109.3% in 2022 and declined 13.81% in 2026, its largest moves.
• Armata Pharmaceuticals' Non-Current Assets stood at $68.8 million in 2022, then increased by 15.16% to $79.2 million in 2023, then declined by 5.15% to $75.1 million in 2024, then declined by 11.87% to $66.2 million in 2025, then decreased by 3.56% to $63.9 million in 2026.
• The last three Non-Current Assets figures came in at $63.9 million (Q1 2026), $66.2 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.